https://www.ndtvprofit.com/business/biocon-soars-nearly-10-on-receiving-nod-from-drugs-controller-general-of-india-for-covid-19-drug-itolizumab-2261677?utm_source=telegram&utm_medium=referral&utm_campaign=socialshare